bioAffinity Technologies price to book ratio BIAF
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 0.4×
- 4-year median
- 1.9×
- Against its 4-year history
- 0th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.4× to 8.1×
- Peer median
- 0.4×
bioAffinity Technologies' price to book ratio is 0.4× as of Oct 23, 2026.
That is below its 4-year median of 1.9×, lower than on 100% of days in the last 4 years.
Over that time it ranged from 0.4× in Oct 2026 to 8.1× in Sep 2024.
The median for 3 healthcare stocks of a similar size is 0.4×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.4× | 2.5× |
| 2025 | 0.6× | 0.6× | 6.8× |
| 2024 | 4.4× | 2.0× | 8.1× |
| 2023 | 2.0× | 1.0× | 2.3× |
| 2022 | 1.1× | 1.1× | 2.0× |
Against its peers
Companies in Healthcare nearest bioAffinity Technologies' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| BIAFbioAffinity Technologies | 0.4× |
| OXBROXBRIDGE RE HOLDINGS | 1.2× |
| EDUCEducational Development | 0.2× |
| GTIMGood Times Restaurants | 0.4× |
| Peer median | 0.4× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on bioAffinity Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.